Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Arantxa Sancho Lopez"'
Autor:
Andrea B. Troxel, Eva Petkova, Keith Goldfeld, Mengling Liu, Thaddeus Tarpey, Yinxiang Wu, Danni Wu, Anup Agarwal, Cristina Avendaño-Solá, Emma Bainbridge, Katherine J. Bar, Timothy Devos, Rafael F. Duarte, Arvind Gharbharan, Priscilla Y. Hsue, Gunjan Kumar, Annie F. Luetkemeyer, Geert Meyfroidt, André M. Nicola, Aparna Mukherjee, Mila B. Ortigoza, Liise-anne Pirofski, Bart J. A. Rijnders, Casper Rokx, Arantxa Sancho-Lopez, Pamela Shaw, Pablo Tebas, Hyun-Ah Yoon, Corita Grudzen, Judith Hochman, Elliott M. Antman
Publikováno v:
JAMA network open, 5(1). American Medical Association
JAMA Network Open
JAMA Network Open
Key Points Question What is the pooled evidence from high-quality randomized clinical trials regarding the safety and potential benefit of convalescent plasma to treat hospitalized patients with COVID-19? Findings In this meta-analysis of 8 randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fe1072863a995e55a314bc38f58afa
https://pure.eur.nl/en/publications/13e7c4e1-4e39-4883-b1b7-82cf5bd0b3cc
https://pure.eur.nl/en/publications/13e7c4e1-4e39-4883-b1b7-82cf5bd0b3cc
Autor:
Inmaculada Palanca-Maresca, Belén Ruiz-Antorán, Pablo del Sol, Gustavo Adolfo Centeno-Soto, Lourdes García Murillo, María Azul Forti-Buratti María Azul Forti-Buratti, Arantxa Sancho Lopez, Laura Javaloyes, Angela Izquierdo, Luz María Solari Hertzmann, Cristina Avendaño-Solá
Background: An increase in prescription of psychotropic medications in children and adolescents has been reported in some countries. We report the evolution in a Health Area in Spain in the period 2013-2017. To describe psychopharmacologic prescripti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d28c60a221a7ebd4afda9777925c5473
https://doi.org/10.21203/rs.2.21668/v1
https://doi.org/10.21203/rs.2.21668/v1
Autor:
Zahra Hanaizi, Beatriz Flores, Arantxa Sancho-Lopez, Francesco Pignatti, Robert Hemmings, Christian Gisselbrecht, Edward Laane, Jorge Camarero, Tomas Salmonson
Publikováno v:
The Oncologist. 20:329-334
On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have receiv
Autor:
Heinz Ludwig, Jorge Camarero Jiménez, Pierre Demolis, Francesco Pignatti, Jonas Bergh, Arantxa Sancho-Lopez, Marc Martin, Edward Laane, Tomas Salmonson, Alexandre Moreau, Christian Gisselbrecht, Isabel Garcia, Kyriaki Tzogani
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist
This article summarizes the scientific review of the application leading to regulatory approval of carfilzomib in combination with lenalidomide and dexamethasone in the European Union.
On November 19, 2015, a marketing authorization valid throug
On November 19, 2015, a marketing authorization valid throug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95139f05d8a85aa0501eaebcfe5bd713
https://hdl.handle.net/20.500.12530/42115
https://hdl.handle.net/20.500.12530/42115
Autor:
Harald Enzmann, Tomas Salmonson, Jorge Camarero, Arantxa Sancho-Lopez, Christoph Unkrig, Christian Gisselbrecht, Zahra Hanaizi, Francesco Pignatti, Edward Laane
On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (Bosulif) for the treatment of adult patients with chronic-phase, accelerated-phase, and blast-phase Philadelphia chromosome positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d39b647d2ca96e08c374d7f3c32678
https://europepmc.org/articles/PMC3983815/
https://europepmc.org/articles/PMC3983815/
Autor:
Jorge Camarero Jimenez, Daniel O’Connor, Arantxa Sancho Lopez, Rosa Giuliani, Isabel García Gallego, Elena Valencia Giménez, Rocio Garcia-Carbonero, Tomas Salmonson, Iordanis Gravanis, Francesco Pignatti, Robert Hemmings
On September 5, 2011, abiraterone was approved in the European Union in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC) in adult men whose disease has progressed on or after a do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ad231ef6f4ccf173f09ddaccd1aaa8
https://europepmc.org/articles/PMC3780635/
https://europepmc.org/articles/PMC3780635/
Autor:
Maaike van Dartel, Zahra Hanaizi, Francesco Pignatti, Arantxa Sancho Lopez, Jorge Camarero, Eric Abadie, Gonzalo Calvo, Barbara van Zwieten-Boot
Publikováno v:
European journal of cancer (Oxford, England : 1990). 48(2)
On 13 July 2011 the European Commission issued a marketing authorisation valid throughout the European Union (EU) for ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy. Ipilimumab